2015 News Releases

Webcast ImageWebcast - Live
Q1 2019 AtriCure, Inc. Earnings Conference Call
04/25/19 at 4:30 p.m. ET
Q1 2019 AtriCure, Inc. Earnings Conference Call
Thursday, April 25, 2019 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure at the Needham & Company’s 18th Annual Healthcare Conference
04/10/19 at 3:30 p.m. ET
AtriCure at the Needham & Company’s 18th Annual Healthcare Conference
Wednesday, April 10, 2019 3:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Q4 2018 AtriCure, Inc. Earnings Conference Call
02/28/19 at 4:30 p.m. ET
Q4 2018 AtriCure, Inc. Earnings Conference Call
Thursday, February 28, 2019 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
12/17/15AtriCure Announces the First Patient Enrolled in International Afib Study
The collaborative study is the first international prospective randomized multicenter study of its kind WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 17, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the CEASE (Combined Endoscopic Epicardial and Percutaneous) AF clinical study. ... 
Printer Friendly Version
11/23/15AtriCure to Present at the Piper Jaffray Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Piper Jaffray Healthcare Conference at the Palace Hotel in New York City on Tuesday, December 1, 2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by v... 
Printer Friendly Version
10/29/15AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Stifel Healthcare Conference at the Palace Hotel in New York City on Wednesday, November 18, 2015. Management is scheduled to present at 2:15 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiti... 
Printer Friendly Version
10/27/15AtriCure Reports Third Quarter 2015 Financial Results
Revenue of $31.4 million – up 17.8% as reported, 20.6% constant currency U.S. sales of $24.7 million – up 23.0% International sales of $6.7 million – up 2.1% as reported, 13.2% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 27, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today anno... 
Printer Friendly Version
10/13/15AtriCure Completes Acquisition of nContact
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 13, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has completed its previously announced acquisition of nContact, Inc., a privately held developer of innovative cardiac ablation solutions. About AtriCure AtriCure, Inc. is a medical device company providing innovative... 
Printer Friendly Version
10/08/15AtriCure to Announce Third Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter of 2015 on Tuesday, October 27, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, October 27, 2015 to discuss its third quarter 2015 financial results. A live webcast of... 
Printer Friendly Version
10/04/15AtriCure Enters Into Definitive Agreement to Acquire nContact
Announces Preliminary Results for Third Quarter 2015, Updates Outlook for 2015 and Provides 2016 Outlook Company to Host Conference Call Monday, October 5 at 8:30am ET Acquisition expands available market opportunity Complementary product lines to provide additional solutions for serious forms of Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 4, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leadi... 
Printer Friendly Version
09/30/15AtriCure Announces Launch of the cryoFORM™ Cryoablation Probe
Offering expands on the company’s cryoablation suite of products by introducing an even more flexible probe for use in a variety of surgical interventions to treat cardiac arrhythmias WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 30, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the launch of the cryoFORM™ cryoablation probe, which... 
Printer Friendly Version
08/21/15AtriCure to Present at the Morgan Stanley Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Friday, September 18, 2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A live audio webcast of the presentation may ... 
Printer Friendly Version
07/28/15AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $32.6 million – up 22.9% as reported, 26.5% constant currency U.S. sales of $25.7 million – up 29.3% International sales of $6.8 million – up 3.5% as reported, 17.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 28, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage m... 
Printer Friendly Version
07/15/15AtriCure to Present at the Canaccord 35th Annual Growth Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 15, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Canaccord 35th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation may be ... 
Printer Friendly Version
07/07/15AtriCure to Announce Second Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the second quarter of 2015 on Tuesday, July 28, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2015 to discuss its second quarter 2015 financial results. ... 
Printer Friendly Version
06/02/15AtriCure to Present at the JMP Securities Life Sciences Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jun. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the JMP Securities Life Sciences Conference at the St. Regis in New York on Wednesday, June 24, 2015. Management is scheduled to present at 9:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiti... 
Printer Friendly Version
04/29/15AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $29.9 million – up 20.3% as reported, 24% constant currency U.S. sales of $22.9 million – up 26.3% International sales of $7.0 million – up 3.9% as reported, 17.6% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, ... 
Printer Friendly Version
04/21/15AtriClip System Surpasses 50,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 50,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, making it not only the preferred surgi... 
Printer Friendly Version
04/08/15AtriCure to Announce First Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the first quarter of 2015 on Wednesday, April 29, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2015 to discuss its first quarter 2015 financial resul... 
Printer Friendly Version
04/07/15AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery
Fellowship provides newly graduated cardiothoracic surgeons with a unique opportunity to be trained by nationally recognized experts in atrial fibrillation surgery WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, together with the American Association for Thoracic Surgery ... 
Printer Friendly Version
03/25/15AtriCure to Present at the Needham Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 25, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 14, 2015. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by... 
Printer Friendly Version
03/18/15AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain
The CryoICE® cryo ablation probe is now available for cryoanalgesia therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 18, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain m... 
Printer Friendly Version
03/05/15AtriCure Announces 2015 Analyst & Investor Meeting
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will host an analyst and institutional investor meeting on Tuesday, March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will include remarks from the AtriCure management team highlighting the company’s strategy for execu... 
Printer Friendly Version
03/03/15AtriCure to Present at the Barclays Capital Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast of the present... 
Printer Friendly Version
02/24/15First Two Patients Enrolled and Treated in AtriCure’s Landmark Afib Study
The collaborative study between cardiac surgeons and electrophysiologists to deliver innovative solutions and new treatment options for Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 24, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced the first two patients have been enrolled and ... 
Printer Friendly Version
02/23/15AtriCure Reports Fourth Quarter and Full Year 2014 Financial Results
2014 revenue of $107.5 million – up 31.2% 2014 U.S. sales of $80.2 million – up 28.7% 2014 International sales of $27.3 million – up 39.2%; 39.8% constant currency Fourth quarter 2014 revenue of $29.4 million – up 34.4% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and l... 
Printer Friendly Version
02/02/15AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 23, 2015 to discuss its fourth quarter and full year 2014 financi... 
Printer Friendly Version
01/19/15AtriCure to Present at the Leerink Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast and replay of the presentation w... 
Printer Friendly Version
01/14/15Douglas Seith Assumes the Role of AtriCure Chief Operating Officer; Andy Wade Promoted to Senior Vice President
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that Douglas Seith will assume the role of Chief Operating Officer. Mr. Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted... 
Printer Friendly Version
01/12/15AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2014 Issues 2015 Guidance
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 12, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced preliminary financial results for fourth quarter and full year 2014 and issued 2015 financial guidance. Preliminary and unaudited revenue for fourth quarter 2014 is expected to be approximately $29.5 million, reflecting growth ... 
Printer Friendly Version